Locally ablative therapies for primary radiation failures: A review and critical assessment of the efficacy

被引:4
作者
Huang W.C. [1 ]
Lee C.L. [1 ]
Eastham J.A. [1 ]
机构
[1] Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
关键词
Prostate Cancer; Radiat Oncol Biol Phys; Localize Prostate Cancer; Ablative Therapy; Recurrent Prostate Cancer;
D O I
10.1007/s11934-007-0009-5
中图分类号
学科分类号
摘要
A significant number of men with prostate cancer will experience biochemical failure following treatment with primary radiation therapy. For patients with biopsy-proven recurrent cancer confined to the prostate, local salvage therapy may be a potentially curative treatment option. Most men, however, do not undergo local salvage therapy owing to difficulties in diagnosis as well as concerns over treatment-related complications in the salvage setting. Recently, improvements in technique and technology have substantially reduced the morbidity associated with locally ablative therapies, resulting in an increased interest in the use of minimally invasive therapies such as brachytherapy, cryotherapy, and high-intensity focused ultrasound in the salvage setting. Although these treatments are well tolerated, concerns remain over incomplete and inadequate treatment with locally ablative therapies. Future studies are required to appropriately select candidates for salvage ablative therapies and to determine the long-term oncologic efficacy of these treatments. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:217 / 223
页数:6
相关论文
共 45 条
[1]  
Jemal A., Siegel R., Ward E., Et al., Cancer statistics, 2007, CA Cancer J Clin, 57, pp. 43-66, (2007)
[2]  
Brandeis J., Pashos C.L., Henning J.M., Litwin M.S., A nationwide charge comparison of the principal treatments for early stage prostate carcinoma, Cancer, 89, pp. 1792-1799, (2000)
[3]  
D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, pp. 969-974, (1998)
[4]  
Lee W.R., Hanks G.E., Hanlon A., Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations, J Clin Oncol, 15, pp. 230-238, (1997)
[5]  
Zagars G.K., Pollack A., von Eschenbach A.C., Prostate cancer and radiation therapy: The message conveyed by serum prostate-specific antigen, Int J Radiat Oncol Biol Phys, 33, pp. 23-35, (1995)
[6]  
Fuks Z., Leibel S.A., Wallner K.E., Et al., The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation, Int J Radiat Oncol Biol Phys, 21, pp. 537-547, (1991)
[7]  
Grossfeld G.D., Li Y.P., Lubeck D.P., Et al., Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor, J Urol, 168, pp. 530-535, (2002)
[8]  
Sylvester J., Grimm P., Blasco J., Et al., The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the United States, Urology, 58, 2 SUPPL. L, pp. 65-70, (2001)
[9]  
Saliken J.C., Donnelly B.J., Rewcastle J.C., The evolution and state of modern technology for prostate cryosurgery, Urology, 60, 2 SUPPL. 1, pp. 26-33, (2002)
[10]  
Poissonnier L., Chapelon J.Y., Rouviere O., Et al., Control of prostate cancer by transrectal HIFU in 227 patients, Eur Urol, 51, pp. 381-387, (2007)